Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Planned Interim Safety Analysis of the Phase 3 Randomized Trial of Selinexor and Lenalidomide Versus Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Patients with Newly Diagnosed Multiple Myeloma (ALLG MM23; Sealand)

Blood (2023) 142 (Supplement 1): 2023.

https://doi.org/10.1182/blood-2023-185169

Published: 2023

Journal Articles

Evaluation of Easym, a Clonotypic Mass Spectrometry Assay, and Euroflow Minimal Residual Disease Assessment in Multiple Myeloma

Jessie Zhao, Tiffany T. Khong, Malgorzata Gorniak, Abir Khaled, Zac McDonald, John Reynolds, Daniel Wong, Nicholas Bingham, Anna M. Johnston, Olga Motorna, Nicholas E. Murphy, Hang Quach, Liqiang Yang, Andrew Spencer

Blood (2023) 142 (Supplement 1): 3328.

https://doi.org/10.1182/blood-2023-179742

Published: 2023

Journal Articles

Efficacy of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma: Primary Analysis of the Australasian Leukaemia & Lymphoma Group NHL29 Study

Emma Verner, Amanda Johnston, Nalini Pati, Eliza Hawkes, Hui-Peng Lee, Tara Cochrane, Chan-Yoon Cheah, Robin J Filshie, Duncan Purtill, Hanlon Sia, Anoop Kumar Enjeti, Christina Brown, Nicholas E. Murphy, Jennifer Curnow, Kenneth Lee, Mannu Walia, Belinda Butcher, Judith Trotman

Blood (2021) 138 (Supplement 1): 304.

https://doi.org/10.1182/blood-2021-149019

Published: 2021

Journal Articles

Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Interim Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02)

Slavisa Ninkovic, Nicholas E. Murphy, Hasib Sidiqi, Craig Thomas Wallington-Beddoe, Anish Puliyayil, Costas K. Yannakou, Wojt Janowski, Flora Yuen, Andrew Spencer, Hang Quach

Blood (2021) 138 (Supplement 1): 1671.

https://doi.org/10.1182/blood-2021-151871

Published: 2021

Journal Articles

Variation in Use of Immunoglobulin and Impact on Survival in Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)

Blood (2021) 138 (Supplement 1): 4757.

https://doi.org/10.1182/blood-2021-147622

Published: 2021

Journal Articles

Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib By Increasing TSP-1-Dependent TGF-β1 Activation in Bone Marrow

Chao Zhang, Xiaoxuan Xu, Timothy Trotter, Amjad Javed, Joanne E. Murphy-Ullrich, Juan Li, Yang Yang

Blood (2021) 138 (Supplement 1): 1575.

https://doi.org/10.1182/blood-2021-149310

Published: 2021

Journal Articles

Antibodies against the erythroferrone N-terminal domain prevent hepcidin suppression and ameliorate murine thalassemia

João Arezes, Niall Foy, Kirsty McHugh, Doris Quinkert, Susan Benard, Anagha Sawant, Joe N. Frost, Andrew E. Armitage, Sant-Rayn Pasricha, Pei Jin Lim, May S. Tam, Edward Lavallie, Debra D. Pittman, Orla Cunningham, Matthew Lambert, John E. Murphy, Simon J. Draper, Reema Jasuja, Hal Drakesmith

Blood (2020) 135 (8): 547–557.

https://doi.org/10.1182/blood.2019003140

Published: 2020

Includes: Supplemental data

Journal Articles

Adeno-Associated Virus Mediated Delivery of a TFPI Antibody Restores Hemostasis in Mouse Model of Hemophilia

Swapnil Rakhe, MS, Reema Jasuja, PhD, Rajani Shelke, Anagha Sawant, Suryanarayan Somanathan, PhD, John E. Murphy, PhD, Debra D Pittman, MS

Blood (2019) 134 (Supplement_1): 3357.

https://doi.org/10.1182/blood-2019-130054

Published: 2019

Journal Articles

Response Rates and Quality of Life Outcomes in Australasian Leukaemia & Lymphoma Group NHL29: A Phase II Study of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma

Emma Verner, MBBS, BMedSci,FRCPA, FRACP, Amanda Johnston, FRACP,FRCPA,MBBS,BMBS,MD, Nalini Pati, MBBS,FRACP,FRCPA, DCH, MD DNB, Eliza A Hawkes, Hui-Peng Lee, MBChB, FRACP, FRCPA, BHB, Tara Cochrane, MBBS,FRCPA,FRACP, Chan Y. Cheah, Duncan Purtill, MBBS,FRCPA,FRACP, Anoop K Enjeti, MBBS,FRCPA, FRACP,PhDMD,MRCP, Christina Brown, PhDFRACP,FRCPA,MBBS, Nicholas E. Murphy, FRCPA,MBBS,FRACP, Jennifer Curnow, MBBS, FRACP, FRCPA, PhD, Julia Carlson, Belinda Butcher, BSci, MBiostat, PhD, Judith Trotman, MBChB, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 4094.

https://doi.org/10.1182/blood-2019-124621

Published: 2019

Journal Articles

Antibodies Against the Erythroferrone N-Terminal Domain Prevent Hepcidin Suppression and Ameliorate Murine Thalassemia

Blood (2019) 134 (Supplement_1): 964.

https://doi.org/10.1182/blood-2019-130246

Published: 2019

Journal Articles

Efficacy and Safety in 15 Hemophilia B Patients Treated with the AAV Gene Therapy Vector Fidanacogene Elaparvovec and Followed for at Least 1 Year

Lindsey A. George, MD, Spencer K. Sullivan, MD, John E.J. Rasko, MBBS, PhD, Adam Giermasz, MD PhD, Benjamin J. Samelson-Jones, MD PhD, Jonathan M. Ducore, MD MPH, Jerome M. Teitel, MD FRCPC, Catherine E. McGuinn, MD, Alexa R. Runowski, MS, Fraser Wright, PhD, Xavier M. Anguela, PhD, Katherine A. High, MD, Denis Rybin, PhD, John E. Murphy, PhD, Jeremy Rupon, MD

Blood (2019) 134 (Supplement_1): 3347.

https://doi.org/10.1182/blood-2019-124091

Published: 2019

Journal Articles

A Neutralizing Monoclonal Antibody (PF-06741086) Against Tissue Factor Pathway Inhibitor in Combination with Activated Prothrombin Complex Concentrate Increases Hemostasis in Inhibitor Hemophilia Plasmas without Excessive Thrombin Generation

Swapnil Rakhe, MS, Sheryl Bowley, PhD, John E. Murphy, PhD, Debra D Pittman, MS

Blood (2018) 132 (Supplement 1): 3779.

https://doi.org/10.1182/blood-2018-99-119831

Published: 2018

Journal Articles

Efficacy of Anti-TFPI Antibody PF-06741086 Alone and in Combination with Activated Prothrombin Complex Concentrates in Mouse Hemophilia a Bleeding Model

Amey Barakat, Reema Jasuja, PhD, John E. Murphy, PhD, Debra D Pittman, MS

Blood (2018) 132 (Supplement 1): 2460.

https://doi.org/10.1182/blood-2018-99-118431

Published: 2018

Journal Articles

The Tissue Factor Pathway Inhibitor Antibody, PF-06741086, Increases Thrombin Generation in Rare Bleeding Disorder and Von Willebrand Factor Deficient Plasmas

Swapnil Rakhe, MS, Sunita R. Patel-Hett, PhD, Sheryl Bowley, PhD, John E. Murphy, PhD, Debra D Pittman, MS

Blood (2018) 132 (Supplement 1): 2462.

https://doi.org/10.1182/blood-2018-99-119674

Published: 2018

Journal Articles

Randomized Trial in Unfit, Elderly Chronic Lymphocytic Leukemia (CLL) Patients with Comorbidities of Dose-Reduced Oral Fludarabine and Cyclophosphamide Plus Obinutuzumab (FC+G) Versus Chlorambucil Plus Obinutuzumab (Cbl+G) As Front-Line Therapy

Stephen P. Mulligan, PhD FRACP, FRCPA, MBBS, Jane A. Freeman, BA, FRACP, FRCPA, MBBS, MPhil, MSc, Xavier Badoux, MBBS, AB, FRACP, FRCPA, Richard Eek, MBCHB, Gavin Cull, MB, BS, DM, FRACP, FRCPA, Naomi J. Mackinlay, MB BS, FRACP, FRCPA, Nicholas E. Murphy, FRCPA, MBBS, FRACP, Duncan P. Carradice, MBBS, FRCPA, FRACP, Ann C. Solterbeck, BSc(hons) MSc PhDAStat, Oliver Giles Best, PhD BSc, Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, Bryone J. Kuss, PhD BMBS, FRCPA, FRACP

Blood (2018) 132 (Supplement 1): 3144.

https://doi.org/10.1182/blood-2018-99-116287

Published: 2018

Journal Articles

Chronic Administration of the PDE9 Inhibitor PF-04447943 Reduces Leukocyte-Platelet Aggregates and Markers of Endothelial Activation in a Mouse Model of Sickle Cell Disease

Reema Jasuja, Elizabeth Parks, John E. Murphy, Debra D Pittman

Blood (2016) 128 (22): 1293.

https://doi.org/10.1182/blood.V128.22.1293.1293

Published: 2016

Journal Articles

An Antibody to Tissue Factor Pathway Inhibitor (PF-06741086) in Combination with Recombinant Factor VIIa Increases Hemostasis in Hemophilia Plasma without Excessive Thrombin Generation

Swapnil Rakhe, Sunita Patel Hett, John E. Murphy, Debra D Pittman

Blood (2016) 128 (22): 2566.

https://doi.org/10.1182/blood.V128.22.2566.2566

Published: 2016

Journal Articles

An Antibody to Tissue Factor Pathway Inhibitor (TFPI) Restores Hemostasis after the Onset of Bleeding in Hemophilic a Mouse Injury Models

Reema Jasuja, Amey Barakat, John E. Murphy, Debra D Pittman

Blood (2016) 128 (22): 3761.

https://doi.org/10.1182/blood.V128.22.3761.3761

Published: 2016

Journal Articles

Rivipansel: A Small Pan-Selectin Antagonist Improves Cerebral Perfusion and Inhibits Leukocyte Adhesion and in Murine Sickle Cell Disease Model

Reema Jasuja, Georgette Suidan, Sunita Patel Hett, Kunal Desai, Kevin X Le, Elizabeth Parks, Robert Bell, John E. Murphy, Debra D Pittman

Blood (2016) 128 (22): 270.

https://doi.org/10.1182/blood.V128.22.270.270

Published: 2016

Journal Articles

Noncovalent stabilization of the factor VIII A2 domain enhances efficacy in hemophilia A mouse vascular injury models

Lilley Leong, Derek Sim, Chandra Patel, Katherine Tran, Perry Liu, Elena Ho, Thomas Thompson, Peter J. Kretschmer, Hironao Wakabayashi, Philip J. Fay, John E. Murphy

Blood (2015) 125 (2): 392–398.

https://doi.org/10.1182/blood-2014-02-555656

Published: 2015

Includes: Supplemental data

NARROW

Planned Interim Safety Analysis of the Phase 3 Randomized Trial of Selinexor and Lenalidomide Versus Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Patients with Newly Diagnosed Multiple Myeloma (ALLG MM23; Sealand)

Evaluation of Easym, a Clonotypic Mass Spectrometry Assay, and Euroflow Minimal Residual Disease Assessment in Multiple Myeloma

Efficacy of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma: Primary Analysis of the Australasian Leukaemia & Lymphoma Group NHL29 Study

Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Interim Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02)

Variation in Use of Immunoglobulin and Impact on Survival in Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)

Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib By Increasing TSP-1-Dependent TGF-β1 Activation in Bone Marrow

Antibodies against the erythroferrone N-terminal domain prevent hepcidin suppression and ameliorate murine thalassemia

Adeno-Associated Virus Mediated Delivery of a TFPI Antibody Restores Hemostasis in Mouse Model of Hemophilia

Response Rates and Quality of Life Outcomes in Australasian Leukaemia & Lymphoma Group NHL29: A Phase II Study of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma

Antibodies Against the Erythroferrone N-Terminal Domain Prevent Hepcidin Suppression and Ameliorate Murine Thalassemia

Efficacy and Safety in 15 Hemophilia B Patients Treated with the AAV Gene Therapy Vector Fidanacogene Elaparvovec and Followed for at Least 1 Year

A Neutralizing Monoclonal Antibody (PF-06741086) Against Tissue Factor Pathway Inhibitor in Combination with Activated Prothrombin Complex Concentrate Increases Hemostasis in Inhibitor Hemophilia Plasmas without Excessive Thrombin Generation

Efficacy of Anti-TFPI Antibody PF-06741086 Alone and in Combination with Activated Prothrombin Complex Concentrates in Mouse Hemophilia a Bleeding Model

The Tissue Factor Pathway Inhibitor Antibody, PF-06741086, Increases Thrombin Generation in Rare Bleeding Disorder and Von Willebrand Factor Deficient Plasmas

Randomized Trial in Unfit, Elderly Chronic Lymphocytic Leukemia (CLL) Patients with Comorbidities of Dose-Reduced Oral Fludarabine and Cyclophosphamide Plus Obinutuzumab (FC+G) Versus Chlorambucil Plus Obinutuzumab (Cbl+G) As Front-Line Therapy

Chronic Administration of the PDE9 Inhibitor PF-04447943 Reduces Leukocyte-Platelet Aggregates and Markers of Endothelial Activation in a Mouse Model of Sickle Cell Disease

An Antibody to Tissue Factor Pathway Inhibitor (PF-06741086) in Combination with Recombinant Factor VIIa Increases Hemostasis in Hemophilia Plasma without Excessive Thrombin Generation

An Antibody to Tissue Factor Pathway Inhibitor (TFPI) Restores Hemostasis after the Onset of Bleeding in Hemophilic a Mouse Injury Models

Rivipansel: A Small Pan-Selectin Antagonist Improves Cerebral Perfusion and Inhibits Leukocyte Adhesion and in Murine Sickle Cell Disease Model

Noncovalent stabilization of the factor VIII A2 domain enhances efficacy in hemophilia A mouse vascular injury models

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only